Syphilis screening coverage and positivity by HIV treatment status among South African pregnant women enrolled in the 2019 antenatal HIV sentinel survey

Show simple item record

dc.contributor.author Kufa, Tendesayi
dc.contributor.author Woldesenbet, Selamawit
dc.contributor.author Cheyip, Mireille
dc.contributor.author Ayalew, Kassahun
dc.contributor.author Kularatne, Ranmini
dc.contributor.author Manda, S.O.M. (Samuel)
dc.contributor.author Lombard, Carl
dc.contributor.author Puren, Adrian
dc.date.accessioned 2024-02-23T13:12:04Z
dc.date.available 2024-02-23T13:12:04Z
dc.date.issued 2023-04-01
dc.description DATA AVAILABILITY : The data that support the findings of this study are available from National Department of Health, South Africa but restrictions apply to the availability of these data, which were collected on behalf of the National Department of Health, South Africa for the current study, and so are not publicly available. Data are however available from the corresponding author Tendesayi Kufa (tendesayikc@nicd.ac.za) upon reasonable request and with permission of National Department of Health, South Africa. en_US
dc.description.abstract We describe coverage of maternal syphilis screening, syphilis positivity, coverage of treatment and their association with maternal HIV infection and antiretroviral treatment (ART) status among pregnant women attending South African antenatal clinics. The 2019 antenatal care sentinel survey was a cross-sectional survey conducted from 1 October to 15 November 2019 at 1589 sentinel sites in all nine provinces of the country and aimed to enrol 36,000 pregnant women ages 15–49 years regardless of HIV, ART or syphilis status. Data collection procedures included obtaining written informed consent, a brief interview, medical record review and blood specimen collection. Completed data collection forms and specimens were sent to designated regional laboratories for data capture and HIV serology testing. Data analysis determined four outcomes i) syphilis screening coverage ii) syphilis positivity iii) coverage of any treatment and iv) with Benzathine penicillin G (BPG). Multivariable logistic regression models with or without interaction between HIV infection and ART status with province were used to determine factors associated with syphilis positivity. Of the 41 598 women enrolled, 35 900 were included in the analysis for syphilis screening coverage. The weighted syphilis screening coverage was 96.4% [95% Confidence Interval (CI) 95.9–96.7%] nationally and was lowest among HIV positive women not on ART at 93.5% (95% CI 92.2–94.5%). Syphilis positivity was 2.6% (95% CI 2.4–2.9%) nationally. Among those who were syphilis positive, 91.9% (95% CI 89.8–93.7%) had documentation of syphilis treatment status, of whom 92.0% (95% CI 89.8–93.9%) were treated, with the majority treated with one or more doses of BPG [92.2% (95% CI 89.8–94.3%)]. HIV-positive women, not on ART [adjusted odd ratio (aOR) 2.24 (95% 1.71–2.93)] and those on ART [aOR 2.25 (95% CI 1.91–2.64)] were more likely to be syphilis positive compared to those who were HIV negative. The national syphilis screening coverage met the global screening target of 95%. Syphilis positivity was higher among HIV positive women compared to negative women. Introduction of rapid syphilis testing and ensuring a universal supply of appropriate treatment for syphilis will reduce the likelihood of mother-to-child transmission of syphilis. en_US
dc.description.department Statistics en_US
dc.description.librarian am2024 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship The President’s Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the National Department of Health (NDoH), and the National Institute for Communicable Diseases (NICD). en_US
dc.description.uri https://www.nature.com/srep en_US
dc.identifier.citation Kufa, T., Woldesenbet, S. Cheyip, M. 2023, 'Syphilis screening coverage and positivity by HIV treatment status among South African pregnant women enrolled in the 2019 antenatal HIV sentinel survey', Scientific Reports, vol. 13, art. 5322, pp. 1-12. https://DOI.org/10.1038/s41598-023-32456-0 en_US
dc.identifier.issn 2045-2322 (online)
dc.identifier.other 10.1038/s41598-023-32456-0
dc.identifier.uri http://hdl.handle.net/2263/94919
dc.language.iso en en_US
dc.publisher Nature Reseach en_US
dc.rights © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License. en_US
dc.subject Syphilis en_US
dc.subject Pregnant women en_US
dc.subject Human immunodeficiency virus (HIV) en_US
dc.subject Maternal syphilis screening en_US
dc.subject Antiretroviral therapy (ART) en_US
dc.subject HIV infection en_US
dc.subject Syphilis positivity en_US
dc.subject Treatment en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title Syphilis screening coverage and positivity by HIV treatment status among South African pregnant women enrolled in the 2019 antenatal HIV sentinel survey en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record